Contact this trialFirst, we need to learn more about you.
Antibody-drug Conjugate
DS-8201a + Olaparib for Endometrial Cancer
Recruiting1 awardPhase 1
Jacksonville, Florida
This trial is testing the side effects and best dose of two drugs, DS-8201a and olaparib, in treating patients with HER2-expressing cancers. Olaparib is a drug that blocks an enzyme involved in many cell functions, including the repair of deoxyribonucleic acid (DNA) damage. DS-8201a is an antibody-drug conjugate. This agent has two components: an antibody component and a chemotherapy component. The antibody component is attached to the chemotherapy molecules. Upon administration of DS-8201a, the antibody targets and binds to tumor cells that have abundant HER2 (
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.